Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasms 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 11fludarabine 8Dexamethasone 7pomalidomide 6pembrolizumab 6Rituximab 5obinutuzumab 4glofitamab 4daratumumab 4Immunotherapy, Adoptive 4Gemcitabine 4Bortezomib 4venetoclax 3selinexor 3fludarabine phosphate 3cemiplimab 3Temozolomide 3Nivolumab 3Melphalan 3Injections 3Etoposide 3zanubrutinib 2tocilizumab 2pirtobrutinib 2blinatumomab 2abemaciclib 2Sirolimus 2Oxaliplatin 2Mesna 2Lisaftoclax 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Tyrosine Kinase Inhibitors × 30 days × Clear all
NCT04777994 2026-06-04

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Calico Life Sciences LLC

Phase 1 Recruiting
248 enrolled
GenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡